Tools
Stock profile

Merck & Co., Inc. (MRK)

MRK · Latest close $137.78 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$137.78
As of Nov 18, 2026
Tracked funds holding
21 of 149
2026 Q2 13F filings
Opened / added
0 / 8
vs previous quarter
Trimmed / exited
7
vs previous quarter

Merck & Co., Inc. (MRK) is held by 21 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 8 funds adding and 7 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $8.6M sold). 1 member of Congress reported 2 purchases vs 1 sale. Latest close $137.78 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 12, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-8.6M
Congress
2 buys vs 1 sale
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Thornburg Investment Management · Kahn Brothers Group · DJE Kapital — 21 tracked funds hold MRK. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 1 sale ($8.6M). Insider trading 1 member of Congress reported buying (2 purchases vs 1 sale). Latest buy: Aug 19, 2026. Politician trading

Often held alongside

PETROBRAS - PETROLEO BRASILEIRO SA (PBR) · ISHARES RUSSELL 2000 ETF (IWM) · TARGET CORP (TGT) · AMERICAN INTERNATIONAL GROUP, INC. (AIG) · Arcos Dorados Holdings Inc. (ARCO) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Thornburg Investment Management4.66%3,787,976ADDED (+1.6%) Q3 filed Nov 13
Kahn Brothers Group4.43%218,182TRIMMED (-4.0%) Q3 filed Nov 16
DJE Kapital3.53%1,431,324ADDED (+9.6%) Q3 filed Nov 12
Mondrian Investment Partners2.92%1,473,945TRIMMED (-6.8%) Q3 filed Oct 23
Oakmark Funds2.06%12,073,109TRIMMED (-2.4%) Q3 filed Nov 16
OrbiMed Advisors1.58%663,400HELD Q3 filed Nov 16
Atalanta Sosnoff Capital1.45%642,053ADDED (+112.5%) Q3 filed Nov 10
Causeway Capital Management1.33%954,932ADDED (+11.8%) Q3 filed Nov 13
Samlyn Capital1.18%565,755TRIMMED (-22.1%) Q3 filed Nov 16
Sarasin & Partners1.11%736,662TRIMMED (-6.2%) Q3 filed Oct 13

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +14.4% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

156.4570.152024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

262016Q3: 22 funds2016Q4: 22 funds2017Q1: 22 funds2017Q2: 22 funds2017Q3: 22 funds2017Q4: 20 funds2018Q1: 19 funds2018Q2: 19 funds2018Q3: 21 funds2018Q4: 23 funds2019Q1: 22 funds2019Q2: 23 funds2019Q3: 25 funds2019Q4: 26 funds2020Q1: 25 funds2020Q2: 21 funds2020Q3: 22 funds2020Q4: 21 funds2021Q1: 22 funds2021Q2: 22 funds2021Q3: 22 funds2021Q4: 21 funds2022Q1: 21 funds2022Q2: 20 funds2022Q3: 21 funds2022Q4: 18 funds2023Q2: 18 funds2023Q3: 20 funds2023Q4: 20 funds2024Q1: 19 funds2024Q2: 20 funds2024Q3: 20 funds2024Q4: 21 funds2025Q1: 17 funds2025Q2: 17 funds2025Q3: 18 funds2026Q1: 21 funds2026Q2: 21 funds2016Q32026Q2

Tracked funds holding this stock, by quarter (2016Q3–2026Q2, 38 quarters). Source: quarterly BEST lists from 13F filings — tracked funds only, not all filers. A stock appears here only if it ever made a quarterly BEST list.

All institutions · Form 13F

Institutions holding3,793 of 8,857 filers
Long-only filers among them3,779
Change vs 2026 Q1+87 net · 2,118 entered · 2,031 exited
Shares reported, all filers1,958,782,160
Reported value, all filers$248.9B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$65.0B
Net income · FY2025$18.3B
Total assets · FY2025$136.9B
Shares outstanding2,467,171,638
Market cap (at latest close)$339.9B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.

Short interest

Shares short · Oct 15, 202626,825,098
Share of shares outstanding1.09%
Days to cover2.97

Shares short at recent settlements — Jul 31, 2026: 28.3M · Aug 14, 2026: 24.5M · Aug 31, 2026: 30.3M · Sep 15, 2026: 34.4M · Sep 30, 2026: 28.3M · Oct 15, 2026: 26.8M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 2K · Sep 15, 2026: 6K · Sep 30, 2026: 6K · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 1 sale by 1 insider ($8.6M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 12, 2026DeLuca Richard R.EVP&Pres, Merck Animal HeallthSell58,185$148.01$8.6MSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Aug 13, 2026CHIRFI GUINDOOfficer10,000$1.4MAug 13, 2026SEC filing
Aug 12, 2026RICHARD ROBERT DELUCA JROfficer11,699$1.5MAug 12, 2026SEC filing
Aug 12, 2026JENNIFER L ZACHARYOfficer80,315$10.7MAug 12, 2026SEC filing
Aug 11, 2026RICHARD ROBERT DELUCA JROfficer12,837$1.7MAug 11, 2026SEC filing
Aug 10, 2026RICHARD ROBERT DELUCA JROfficer20,784$2.7MAug 10, 2026SEC filing
Aug 6, 2026CHIRFI GUINDOOfficer15,000$2.0MAug 6, 2026SEC filing
Aug 6, 2026RICHARD ROBERT DELUCA JROfficer6,050$788.8KAug 6, 2026SEC filing
Aug 5, 2026DAVID M WILLIAMSOfficer52,847$6.8MAug 5, 2026SEC filing
Aug 5, 2026DAVID MARALDOOfficer18,706$2.4MAug 5, 2026SEC filing
Feb 13, 2026CHIRFI GUINDOOfficer20,000$2.4MFeb 9, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Apr 30, 2026Vanguard Capital ManagementSC 13G186,323,7667.5%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Mar 6, 2025The Vanguard GroupSC 13G/A253,257,63910.0%Feb 28, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

1 member of Congress reported buying (2 purchases vs 1 sale). Bought by Republicans. Latest buy: Aug 19, 2026.

Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.

Recent activity by member

MemberChamberPartyBuysSellsLatestAmount range
Salazar, Maria ElviraHouseR21Sep 24, 2026$15,001 - $50,000

Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 921 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Health Issues (611), Medicare/Medicaid (553), Taxation/Internal Revenue Code (341).

Federal contracts: $2.5B in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$1.3B
FY2022$998.3M
FY2023$36.9M
FY2024$155.5M
FY2025$6.5M
FY2026$3.0M

Largest awards collected

Award IDAgencyAmountStart
W911QY21C0031Department of Defense$2.2BJun 7, 2021
HHSD200201458150CDepartment of Health and Human Services$1.5BApr 1, 2014
HHSD200201793273CDepartment of Health and Human Services$1.5BApr 1, 2017
HHSD200201354509CDepartment of Health and Human Services$1.4BApr 1, 2013
HHSD200201250133CDepartment of Health and Human Services$1.4BApr 1, 2012

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Politicians

· Bought by Members — Last 6 months: bought by a member of the U.S. Congress

Financial Screens

· Growth — Revenue up every year for 5 straight years

· Graham — Sound finances and a long run of profits

· Lynch PEG — Cheap against its growth rate

· Dividend Growth — Dividends raised for more than 10 years

· Neff Total Return Ratio — Growth plus dividends divided by P/E is high

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

· Shareholder Yield — Cash returned through dividends and buybacks

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Key figures

· Growth — Latest revenue: $65.0B · 5-yr revenue CAGR: 9.4% · Straight growth years: 6

· Graham — Current ratio: 1.54 · Straight profitable years: 19 · Debt ratio: — · Latest net income: $18.3B

· Lynch PEG — P/E: 20.10 · 5-yr EPS growth: 21.2% · PEG: 0.95

· Dividend Growth — Dividend per share: 3.28 · Dividend yield: 2.2% · Straight dividend years: 19 · 10-yr dividend growth: 77.3%

· Neff Total Return Ratio — EPS growth: 21.2% · Dividend yield: 2.2% · P/E: 20.10 · Neff ratio: 1.17

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 12.60 · Operating cash flow: $16.5B · Net income: $18.3B

· Shareholder Yield — Shareholder yield: 3.6% · of which dividends: 2.2% · of which buybacks: 1.4%

· Bought by Members — Members buying: 1 · Buy txns: 2 · Sell txns: 1 · Latest buy: Aug 19, 2026

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Super-investor 13F BEST — appeared in 38 of the last 40 quarterly lists; latest 2026 Q2, ranked #30 of 50.

· Politician BEST — appeared in 11 of the last 20 quarterly lists; latest 2025 Q3, ranked #45 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together1050.0%+4.8%+2.1%+2.7%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold MRK — ranked by lift, the co-holding pattern described in Methodology: PETROBRAS - PETROLEO BRASILEIRO SA (PBR) · ISHARES RUSSELL 2000 ETF (IWM) · TARGET CORP (TGT) · AMERICAN INTERNATIONAL GROUP, INC. (AIG) · Arcos Dorados Holdings Inc. (ARCO) · BARCLAYS PLC (BCS) · EQUINOR ASA (EQNR) · ISHARES RUSSELL 1000 ETF (IWB).

Filings audit: every filing lens on Merck & Co., Inc. (MRK), scored — GetCoattail Research.

Recent 8-K filings

FiledItemsSource
Nov 18, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 9.01 Financial Statements and ExhibitsSEC filing
Oct 29, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Oct 13, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain OfficersSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

PETROBRAS - PETROLEO BRASILEIRO SA (PBR) · Filings audit: every filing lens on Merck & Co., Inc. (MRK), scored · Practice timing on MRK

One email a week: the week’s new filings and research. Subscribe free

← MREO  ·  MRKR →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.